Moneycontrol PRO

IPCA Labs guidance should move investor focus beyond HCQS, accumulate

There is much more to IPCA Labs than the HCQS opportunity. Its FY21 guidance reflects that.

July 06, 2020 / 05:32 PM IST
IPCA Labs guidance should move investor focus beyond HCQS, accumulate

Bharat Immunologicals & Biologicals Corporation | In the last four months, the stock price has risen 444 percent to Rs 31.34 per share from Rs 5.76 per share on March 27, 2020.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Anubhav Sahu Moneycontrol Research - Strong HCQS sales in Q1 FY21 though uncertainty increases for future demand - Strong operating performance and guidance brings focus beyond HCQS - FY21 guidance for 15% plus sales growth and margin expansion of 150 bps - Resolution of US FDA import alerts and environment clearances - key near term watch IPCA Labs (CMP: Rs 1,662, Market cap: Rs 21,008 crore) had been on the radar of investors as the anti-malarial drug HCQS (hydroxychloroquine sulphate) was seen as a drug of choice...

  • PRO Panorama

    Moneycontrol Pro Panorama | GST: A simple, reliable tax still a distant dream?

    May 20, 2022 / 04:41 PM IST

    In today’s edition of Moneycontrol Pro Panorama: A peek into Strategy Lab, ITC makes it to Weekly Tactical, wide canvas for Nazara, shock proof your portfolio and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | People’s Bank of China rides to the rescue 

    May 21, 2022 / 10:10 AM IST

    The central bank of China – an outlier in these times of quantitative tightening – has eased its policy to salvage the Chinese economy. And the messaging is not lost on global growth

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers